Compare Enveric Biosciences Inc (ENVB) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MSCI India ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares MSCI India ETF trades at $46.03 (market cap $5.81B). The key difference: iShares MSCI India ETF is far larger — about 868.5× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (41,141 versus 5,590,429). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares MSCI India ETF for 57 Days on average.
| ENVB | INDA | |
|---|---|---|
Market Cap | $6.69M | $5.81B |
Volume | 41,141 | 5,590,429 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $55.29 |
52-Week Low | $1.27 | $45.42 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
INDA is trading at $46.12, down 1.31% with a bearish technical signal across moving averages and oscillators. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Technical indicators show oversold conditions with RSI readings below 30, while support and resistance cluster around $46.
The outlook remains cautious given India's infrastructure constraints and global trade tensions. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy security concerns, weather-related agricultural impacts, and IT sector weakness. Current technical oversold conditions may present entry points for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
